ABSTRACT Increasing resistance to antimicrobial agents is of growing concern to public health officials worldwide. The concern includes infections acquired in hospitals, community infections acquired in outpatient care settings, and resistant foodborne disease associated with drug use in food-producing animals. In the United States, a significant source of antimicrobialresistant foodborne infections in humans is the acquisition of resistant bacteria originating from animals. The US Food and Drug Administration's (FDA's) goal in resolving the public health impact arising from the use of antimicrobial drugs in food-producing animals is to ensure that significant human antimicrobial therapies are not compromised or lost while providing for the safe use of antimicrobials in food animals. The FDA's approach to the problem is multipronged and innovative. The strategy includes revision of the pre-approval safety assessment for new animal drug applications, use of risk assessment to determine the human health effect resulting from the use of antimicrobials in food animals, robust monitoring for changes in susceptibilities among foodborne pathogens to drugs that are important both in human and veterinary medicine, research, and risk management.
INTRODUCTION
The increase in resistance of bacteria to drugs used to treat human infections has raised questions about the role that antimicrobial drug use in food-producing animals plays in the emergence of antimicrobial drug-resistant bacteria. The use of antibiotics to treat disease in food-producing animals started in the mid-1940s. The introduction of antibiotics in commercial feed for cattle, pigs, and chickens began in the early 1950s. The scientific debate over the potential public health risks from animal use of antibiotics arose more than 30 years ago when researchers first reported that the addition of streptomycin to chicken feed increased the growth rate of chickens 1 .
In recent years, concerns about the use of antimicrobial products in food-producing animals have focused on human food safety because foods of animal origin are vehicles of foodborne disease in humans. The selection of drug-resistant bacterial populations is a consequence of exposure to antimicrobial drugs and can occur from human, animal, and agricultural uses. The administration of these compounds to food-producing animals is necessary to maintain their health and welfare. However, food-producing animals can become reservoirs of bacteria capable of being transferred on food. Foodcarrying resistant bacterial pathogens can cause human illness and subsequent therapeutic failure to mitigate these infections. Many of the antimicrobials used to treat animals are either identical to or related to drugs used in human medicine, including penicillins, tetracyclines, cephalosporins, and fluoroquinolones. Many of these drugs are also used to treat foodborne disease in humans. In industrialized countries, Salmonella and Campylobacter are infrequently transferred from person to person. In these countries, epidemiological data have demonstrated that a significant source of drug-resistant foodborne infections in humans is the acquisition of resistant bacteria originating from animals [2] [3] [4] . This source of infection has been demonstrated through several different types of foodborne disease follow-up investigations, including laboratory surveillance, molecular subtyping, outbreak investigations, and studies on infectious dose and carriage rates [4] [5] [6] . Holmberg et al were the first to document an outbreak of salmonellosis in people, caused by multidrug-resistant Salmonella. People were infected after eating hamburger originating from South Dakota beef cattle fed chlortetracycline for growth promotion 4 . More recent studies have confirmed that using antimicrobial drugs in animals increases the risk of selecting for resistant foodborne pathogens, and that these pathogens can then be transferred to humans through direct contact with either contaminated food or animals 7, 8 . In 1986, Cohen and Tauxe published a review of infections caused by drug-resistant Salmonella in the United States 3 . Using data from prospective studies conducted by the Centers for Disease Control and Prevention (CDC) on Salmonella, the authors showed that there was no correlation between antimicrobial drugs used to treat salmonellosis in humans and the antimicrobial pattern of resistance among Salmonella isolated from either human or animal sources. However, a great deal of similarity was found between resistance patterns in Salmonella isolates from animals and humans and antimicrobial drugs used in farm animals 3 . CDC epidemiologists have recently updated and confirmed these findings with more current data and have determined that antimicrobial use in humans contributes little to the emergence and development of antimicrobial-resistant Salmonella in the United States 2 .
Since human use of antimicrobial drugs is not a significant contributor to development of resistant Salmonella strains, it is likely that the majority of antimicrobial-resistant Salmonella in humans and foodproducing animals is the result of antimicrobial drug use in food-producing animals. This assumption does not require that every food-producing animal carrying resistant Salmonella had to have been treated with an antimicrobial drug. Resistant organisms can be acquired from an environment contaminated by drug use in a previous herd or flock of animals. Resistant organisms can also be acquired through contact with other animals during transportation to the slaughter plant and antemortem processing, through cross-contamination at the time of slaughter or harvest or at various postslaughter or harvest processing points, or through the contamination of food in the home by contact with raw products containing these resistant pathogens. There are a limited number of mechanisms by which bacteria acquire resistance to these compounds. Bacterial resistance may develop by mutation of genes that code for drug uptake into cells or the binding sites for antimicrobial agents, or by acquiring foreign DNA capable of mediating resistance. The genes encoding resistance determinants may be located on the chromosome where they are inherited by daughter cells. Alternatively, resistance genes might be horizontally transmitted to pathogenic and commensal bacteria on mobile DNA elements such as plasmids and transposons. Most resistance genes reside on mobile DNA elements, some of which can spread to diverse and unrelated bacterial species. Animal enteric bacteria that are nonpathogenic to humans may then pass resistance traits to pathogenic bacteria. Mobile genetic elements often carry several resistance genes, and, consequently, the uptake of a single mobile genetic element may confer resistance toward multiple antimicrobials 9 . Moreover, structurally different classes of antimicrobial drugs may select for resistance to unrelated drug classes that have a common site of action 10 .
HISTORICAL BACKGROUND Soon after livestock producers began using antimicrobials in food-producing animals, scientists began studying the possible human health effects of their long-term use. In 1969, the Swann Committee was formed in the United Kingdom to review these concerns and was the first to link an outbreak of salmonellosis in humans to therapeutic use of antibiotics in sick calves 11 . The Committee recommended that antibiotics used in animals be divided into feed and therapeutic classes; the feed antibiotic class should not include drugs used therapeutically in humans or animals, and therapeutic antibiotics should be available only by prescription 11 .
A 1970 US Food and Drug Administration (FDA) Task Force examined the issue and found that use of antibiotics in animal feeds is associated with the development of resistant bacteria. The Task Force concluded that treated animals may serve as a reservoir of antibiotic-resistant pathogens that can produce human disease. In 1977, FDA proposed to withdraw the subtherapeutic uses of penicillin and tetracyclines from animal feeds. These 2 drugs were chosen because of their importance in human medical therapy. The proposal was criticized because, at that time, there was not adequate epidemiological evidence (or only just-emerging evidence) to show that drug-resistant bacteria of animal origin are commonly transmitted to humans and cause serious illness. Critics argued that while antibiotics used in animals select for resistant bacteria, the transfer of these bacteria from animals to humans is rare. In 1984, the Natural Resources Defense Council, Inc (NRDC) petitioned the Department of Health and Human Services (HHS) to immediately suspend approval of the subtherapeutic use of penicillin and tetracyclines in animals by invoking the imminent hazard provision of the Food, Drug, and Cosmetic Act. This provision authorizes the Secretary of HHS to suspend the marketing of an animal drug if an imminent hazard exists to the health of humans or to the animals for which the drug is intended. NRDC based its petition primarily on the study by Holmberg et al 4 that linked drug-resistant salmonellosis in humans to consumption of hamburger. FDA denied the petition based on limited evidence of a human health hazard. In 1988, the Institute of Medicine reviewed all of the available information about the antimicrobial resistance issue. An expert Committee was convened to determine the human health risks associated with the practice of feeding subtherapeutic levels of penicillin and tetracyclines to animals for growth promotion, feed efficiency, and disease prevention. In the report, Human Health Risks with the Subtherapeutic Use of Penicillin or Tetracyclines in Animal Feed, the Committee developed a risk-analysis model using data only on Salmonella infections that resulted in human death 12 . The Committee found a considerable amount of indirect evidence implicating both subtherapeutic and therapeutic use of antimicrobials as a potential human health hazard. However, the Committee did not find data demonstrating that use of subtherapeutic penicillin or tetracycline directly caused humans to die from salmonellosis. The Committee noted that it was not possible to separate the public health effects of therapeutic and subtherapeutic uses and strongly recommended further study of the issue 12 .
The American Society of Microbiology (ASM), which includes members who specialize in medical and animal microbiology, issued a report in 1995 that cited grave concerns both about human and animal antibiotic use and about the rise in antimicrobial resistance 13 . The report advocated a significant increase in resistance monitoring in the US, more education about the use and risks of antimicrobials, and more basic research designed to develop new antimicrobials, vaccines, and disease prevention measures. The report not only criticized the overuse of antibacterials in human medicine but also pointed out the extensive use in foodproducing animals. The report also made it clear that resistance is a global problem. The ASM report was a precursor to involvement by the United Nations' World Health Organization (WHO). In October 1997, WHO convened a meeting of experts in Berlin, Germany, to review the question of whether the use of antimicrobials in animals leads to antimicrobial resistance in humans. The experts sought to define potential medical problems that could arise from antimicrobial use in livestock and to recommend the actions that WHO should take in this regard. The group recommended against the use of animal growth promoters that may be prescribed for use as antiinfective agents in human medicine or that can induce cross-resistance to antimicrobials used for human medical therapy 14, 15 . The group also recommended that research be conducted on nonantimicrobial growthpromoters and urged that the risk to human health from use of antimicrobials in food animals be accurately assessed. These experts called for enhanced monitoring of resistance among isolates of enteric bacteria from food animals and food of animal origin. In addition, the group recommended managing risk at the producer level through the prudent use of antimicrobials 15 . In June 1998, the WHO held another meeting in Geneva, Switzerland, to specifically address the use of quinolones in food-producing animals. The participants agreed that the use of antimicrobials will cause resistance to develop and that there is a potential human health hazard from resistant Salmonella, Escherichia coli, and Campylobacter organisms transferred to humans through the food supply 16 . However, the experts also agreed that antimicrobial drugs, including quinolones in certain instances, are needed to treat sick animals and urged more research on the possible human health effects from the use of these drugs in animals 16 . The Scientific Steering Committee of the European Commission published a report on antimicrobial resistance in May 1999 17 . The Committee concluded that actions should be taken promptly to reduce the overall use of antimicrobials. Four primary recommendations were forwarded: (1) antimicrobial drugs should be used prudently; (2) infections should be prevented and resistant organisms contained; (3) research for new modalities of prevention and treatment of infections should be undertaken; and (4) effects of interventions should be monitored and evaluated. In December 1998, on the basis of newly available information and the ongoing work of this Committee, the agriculture ministers in the EU voted to ban 4 antibiotics that are widely used at subtherapeutic levels to promote animal growth. The ban on using bacitracin zinc, spiramycin, tylosin, and virginiamycin in animal feed became effective for the 15 member states of the EU on July 1, 1999. Individual countries other than the United States are also studying the human health impact of antimicrobial drug use in food-producing animals. The Joint Expert Technical Advisory Committee on Antibiotic Resistance (JETACAR) was appointed in 1998. They were charged by the Australian Minister for Health and Family Services and the Minister for Primary Industries and Energy to examine the issue of antimicrobial resistance from a scientific perspective 18 . The Committee consisted of experts from public health, human and veterinary medicine, molecular biology, and several industries. After reviewing the scientific evidence on the link between the use of antimicrobial agents in foodproducing animals with the emergence of resistant bacterial strains and their subsequent spread to humans, the Committee generated recommendations for future management of antimicrobial drug use in food-producing animals. Key stakeholders were invited to provide input in the form of scientific data during the Committee deliberations and during the drafting of the report, which was published in March 1999 and finalized in September 1999. The JETACAR concluded that there is a human health hazard associated with the use of anti-infective agents in food-producing animals, but that this hazard must be weighed against the importance of antimicrobials to veterinary medicine, food productivity, and animal welfare The purpose of the expert consultation was to develop global principles for minimizing the negative public health impact associated with the use of antimicrobial agents in food-producing animals, while providing for their safe and effective use in veterinary medicine. These principles are part of a comprehensive WHO global strategy for the containment of antimicrobial resistance and provide a framework of recommendations to reduce the overuse and misuse of antimicrobials in food animals for the protection of human health. The principles strengthen and endorse earlier WHO recommendations such as the need to terminate the use of antimicrobial growth promoters pending comprehensive human health safety evaluations, and the need to establish surveillance systems on antimicrobial drug consumption 20 .
CURRENT NEW ANIMAL DRUG APPROVAL PROCESS
The FDA is charged with the regulatory responsibility of ensuring that the use of antimicrobial drugs in food-producing animals does not result in adverse health consequences in humans.
Before any animal drug may be legally marketed in the United States, the drug sponsor must have a New Animal Drug Application (NADA) approved by the FDA. To obtain NADA approval, the drug's sponsor must demonstrate that the drug is effective and safe for the animal, safe for the environment, and can be manufactured to uniform standards of purity, strength, and identity. If the animal drug product is intended for use in food-producing animals, the drug's sponsor must also demonstrate that edible products derived from treated animals are safe for consumers 21 . Accordingly, for antimicrobial compounds, there are 2 major concerns that must be addressed: (1) the human food safety of veterinary drug residues and (2) the potential for encouraging the emergence of resistant bacteria of human health concern.
Human Food Safety of Veterinary Drug Residues
To determine the food safety of residues of an antimicrobial product, the drug sponsor conducts a standard battery of toxicology tests. The battery includes studies that examine the effect of the product on systemic toxicity, genotoxicity/mutagenicity, and reproductive and developmental toxicity. The toxicology studies are designed to identify a dose that causes a toxic effect and a dose that causes no observed effect. Once the no-observed-effect level is established for all the toxicity end points, sponsors must identify the most sensitive effect in the species deemed to be the most predictive of effects in humans. This no-observed-effect level is divided by a safety factor (both to account for uncertainty in extrapolating from animals to humans and to adjust for potential interindividual variability) to calculate an acceptable daily intake (ADI) of drug residues. The ADI represents the amount of drug residues that can be safely consumed daily for a lifetime. Once the ADI is established, the drug's sponsor conducts drug metabolism and depletion studies. The tissue in which the drug depletes the slowest is established as the target tissue and the amount of drug that can be measured with a regulatory method is established as the tolerance. When the drug residue in the target tissue depletes below the tolerance, all edible tissues are considered safe for human consumption 21 . There are special food safety concerns for the residues of antimicrobial drugs 22 . It is known that therapeutic doses of these agents can cause adverse effects on the human intestinal microflora. Therefore, the agency has determined that issues of public health concern include the impact of drug residues in food on the selection of resistant bacteria, perturbation of the barrier effect within the human intestine, changes in intestinal enzymatic activity, and alteration in intestinal bacteria counts. A perturbation in the barrier effect is of concern because the gut microflora provides a barrier against the overgrowth and invasion of pathogenic bacteria. When an anti-infective agent destroys this barrier, overgrowth of pathogenic bacteria may occur.
Human Food Safety of Drug-Resistant Pathogens
Based on the increasing evidence that use of antimicrobials in food-producing animals may select for resistant bacteria of public health concern, the FDA published new guidance in 1999 23 . The guidance states that the FDA believes it is necessary to consider the potential human health impact of the antimicrobial effects associated with all uses of all classes of antimicrobial new animal drugs that are intended for use in food-producing animals. Minimizing the emergence of antimicrobial-resistant bacteria in animals and their subsequent spread to humans through the food supply is a complex problem requiring a coordinated, multifaceted approach. The strategy developed by the FDA to address antimicrobial resistance is 1 component of more broad-reaching strategies being developed at the national level in the form of the Public Health Action Plan to Combat Antimicrobial Resistance 24 . The Federal Public Health Action Plan demonstrates a coordinated focus on, among other areas, education, surveillance, research, and product development. Implementation of new policies for ensuring the safety of new animal antimicrobial drugs with regard to their microbiological effects is a top priority action item of the federal plan. Unfortunately, unlike the clearly defined mechanism for ascertaining the toxicological safety of drug residues in food, no such predictive models currently exist to precisely estimate the rate and extent of bacterial resistance that may emerge from the use of antimicrobial drugs in food-producing animals. Despite the current lack of such models, certain information can be generated to support a pre-approval antimicrobialresistance safety assessment.
FDA outlined in a 1999 discussion document, Proposed Framework for Evaluating and Assuring the Human Safety of the Microbial Effects of Antimicrobial New Animal Drugs Intended For Use in Food-Producing
Animals (the Framework Document), possible strategies for managing the potential risks associated with the use of antimicrobial drugs in food-producing animals 25 . The Framework Document describes both pre-approval and post-approval approaches. The strategies include (1) categorization of antimicrobial drugs based on the importance of the drug for human medicine; (2) revision of the pre-approval safety assessment for antimicrobial resistance for new animal drug applications to include an evaluation of all uses for microbial safety; (3) postapproval monitoring for the development of antimicrobial drug resistance; (4) collection of food animal antimicrobial drug use data; and (5) the establishment of regulatory thresholds. The Framework Document, as well as the individual strategies outlined, has been the subject of a number of public meetings.
NEW REGULATORY STRATEGY FDA is currently
drafting guidance for industry that incorporates the concepts previously described in the Framework Document and outlines a general strategy for regulating the use of antimicrobial drugs in food-producing animals. This guidance will incorporate the basic strategies of the Framework Document into a single, coordinated, and comprehensive plan.
Drug Categorization
A key component of the Framework Document is the concept of categorizing antimicrobial drugs according to their importance for treating disease in humans. The Framework Document discusses 3 categories, with the most important drugs being considered Category I. The categorization process is an integral part of assessing safety in that it provides a mechanism for characterizing the potential human health impact resulting from treatment failure due to resistance. The categorization process also serves to focus the greatest level of attention on those antimicrobial drugs of greatest importance to human medical therapy.
Pre-approval Product Review
Consistent with the risk-based approach outlined in the Framework Document, applications for antimicrobial drugs for food-producing animals will initially undergo an antimicrobial resistance risk assessment. The antimicrobial resistance risk assessment will coalesce a broad set of information regarding the drug and the proposed drug use. This assessment will characterize the proposed drug product as to the potential for resistance to emerge in animals, the potential that such resistance would be transmitted from animals to humans, and the potential consequence of that resistance to human health. These factors taken together will be used to characterize the overall risk that the proposed drug use in animals would cause antimicrobial resistance to emerge and to impact human health.
In addition to the risk assessment, applications for antimicrobial drugs for food-producing animals will undergo a risk management assessment. The recognition that the use of antimicrobial drugs exerts microbial selection pressure focuses attention on the need for appropriate or judicious use of antimicrobial drugs. A principle consistent with the judicious use concept is the idea that certain drugs, or certain druguse conditions, are more (or less) likely than others to exert pressures favorable to the emergence of resistance. This risk-based approach to characterizing antimicrobial drugs is consistent with the basic concepts outlined in the Framework Document 25 . That is, risk management steps would be scaled to account for differing levels of risk associated with certain drugs and certain drug use conditions. Based on the conclusions of the antimicrobial resistance risk assessment completed prior to drug approval, the defined risk may be most appropriately managed, for example, by approving only limited use conditions for a particular drug entity. Use restrictions may include limitations regarding product marketing status, extra-label use provisions, or dosage and administration instructions.
Post-Approval Monitoring

US NATIONAL ANTIMICROBIAL RESISTANCE MONITORING SYSTEM FOR ENTERIC BACTERIA A
key component of FDA's overall strategy on antimicrobial resistance is a national surveillance program that monitors resistance among enteric pathogens in both animals and humans. In 1996, the FDA, the CDC, and the US Department of Agriculture (USDA) established the National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS) to prospectively monitor changes in antimicrobial susceptibilities of zoonotic enteric pathogens from human and animal clinical specimens, from carcasses of food-producing animals at slaughter, and from retail food 26 . NARMS is currently monitoring susceptibilities of human and animal isolates of nontyphoid Salmonella and E coli to 18 antimicrobials (Table 1) and Enterococcus isolates to 17 antimicrobials (Table 2 ). Campylobacter isolates are tested for susceptibility to azithromycin, chloramphenicol, ciprofloxacin, clindamycin, erythromycin, gentamicin, nalidixic acid, and tetracycline. Human isolates of Salmonella typhi and Shigella are also tested. The antimicrobial panels are reviewed annually. Antimicrobials are selected for testing based on their importance in human or veterinary medicine; minimum inhibitory concentration ranges are chosen to detect incremental changes in resistance based on the previous 2 years of data. The goals and objectives of the monitoring program are to provide descriptive data on the extent and temporal trends of antimicrobial susceptibility in enteric organisms from the human and animal populations; provide information to veterinarians, physicians, and public health authorities so that timely action can be taken; prolong the life span of approved drugs by promoting the prudent use of antimicrobials; identify areas for more detailed investigation; and guide research on antimicrobial drug resistance. Annual reports summarizing the data are available on the Internet at (http://www.fda.gov/cvm/mappgs/narms.htm and www.cdc.gov/ncidod/dbmd/narms). The NARMS was substantially expanded under the National Food Safety Initiative. Veterinary diagnostic lab sentinel sites were enrolled and the number of Salmonella isolates collected from slaughter plants greatly increased. Retail food testing was added in 2001 as a pilot study and plans are under way to enhance this aspect of the program in 2002 and beyond. In addition, each NARMS testing site now has the expertise of a molecular biologist to facilitate associated analytical microbiological research on the NARMS isolates, including molecular characterization. Follow-up epidemiology research and investigations augment the program. Two projects on prudent drug-use activities on dairy farms were supported in California and Michigan and similar projects in swine at Tufts University and The Ohio State University were funded in late 2001. On-farm poultry studies, designed to elaborate management, production, and drug-use practices that influence the development of resistant zoonotic pathogens, were supported in 5 states. Support has also been provided to the American Veterinary Medical Association to develop judicious use principles for beef, dairy, swine, and poultry practitioners. The FDA recently printed these principles in booklet form and produced 2 videotapes for educational purposes. Additional booklets designed to provide food animal producers the background to the judicious use principles are under development. The NARMS program is integral to FDA's strategy of enhanced pre-approval assessment, postapproval surveillance, and regulatory controls in order to better characterize and control the development of antimicrobial resistance. Early identification of emerging resistance will facilitate management of the problem as well as development of educational efforts on the appropriate use of antimicrobial agents. Monitoring will also allow assessment of the impact of these efforts.
MONITORING USE OF ANTIMICROBIAL DRUGS IN FOOD-PRODUCING ANIMALS FDA currently requires
the submission of certain drug sales information as part of the annual drug experience report for approved drug products. The Framework Document identified the need for the pharmaceutical industry to submit more detailed antimicrobial drug sales information as part of its annual drug experience report. The goal of this additional monitoring is to obtain objective and quantitative information with which to evaluate usage patterns according to antimicrobial agent or class, animal species, route of administration, and type of use (eg, therapeutic or growth promotion. These data are essential for risk analysis and planning, can be helpful in interpreting resistance surveillance data obtained through NARMS, and can assist in the response to the detection of antimicrobial resistance in precise and targeted ways not previously possible. These data can also be used to evaluate the effectiveness of mitigation strategies implemented in response to trends of increasing resistance and to assess the success of prudent drug-use initiatives. The FDA is developing new requirements for antimicrobial drug-use information through a notice and comment rule-making process.
RESEARCH ACTIVITIES
Research provides the knowledge necessary to understand the fundamental processes involved in antimicrobial resistance and its impact on humans, animals, and the environment, and to develop appropriate responses. An extensive knowledge base has been developed, but more research is needed on the relationship between antimicrobial use in food animals and the associated human health impact related to antimicrobial resistant bacteria. Such research is important for guiding the FDA in further refining its preapproval and postapproval activities.
The FDA Center for Veterinary Medicine has initiated its own intramural and collaborative research efforts to investigate factors associated with development, dissemination, and persistence of antimicrobial resistance in both the animal production environment and the food supply. FDA microbiologists are currently conducting or are participating in projects specifically targeted to gather data on such issues as the following: (1) the background level of antimicrobial resistance that currently exists in retail animal-derived food products; (2) the development and persistence of antimicrobial resistance from aquaculture and animal production environments; (3) characterization of mechanisms of resistance dissemination and transfer among pathogenic and commensal bacteria associated with food-producing animals and aquaculture environments; (4) determining the roles that animal feeds and feed commodities play in the dissemination of antimicrobial resistance and pathogen carriage; and (5) coselection of resistant phenotypes associated with the use of sanitizers and antimicrobial drugs in animals. In addition, the Center for Veterinary Medicine is a contributing laboratory to CDC's PulseNet molecular fingerprinting network involved in the molecular epidemiology of foodborne outbreaks. The Center's laboratory provides the only source of data on animal-associated bacterial pathogens into the PulseNet system. In addition to the intramural research, FDA also collaborates in extramural research grants and funds extramural research activities through cooperative agreements. This extramural research is designed to complement and augment the intramural research program. The Center for Veterinary Medicine is also developing methods for conducting antimicrobial resistance risk assessments to better characterize and quantify the human health impact associated with antimicrobial drug use in food-producing animals. A quantitative risk assessment has been completed with regard to fluoroquinolone use in poultry and a second risk assessment on the use of virginiamycin is in progress. The fluoroquinolone risk assessment is a model for the direct transfer of resistance, a situation in which the resistant bacteria are transferred from animals to humans as a food contaminant. An ongoing risk assessment regarding virginiamycin use in foodproducing animals, on the other hand, attempts to model the indirect transfer of resistance, where resistant determinants are passed among bacteria in the human gut flora. The Center for Veterinary Medicine is considering how the models developed in these risk assessments may be applied to other antimicrobial agents.
DISCUSSION
The relationship of the use of antimicrobial drugs in food-producing animals and the emergence of resistant bacteria in the food chain has been the subject of numerous national and international consultations.
The prevention and control of antimicrobial resistance in agriculture and veterinary medicine require a concerted effort by all stakeholders, including regulatory agencies, the veterinary pharmaceutical industry, veterinarians, and livestock producers. FDA is responsible for developing a regulatory framework to assess the safety of antimicrobial drugs used in food-producing animals with respect to their propensity to cause resistance in bacteria that can be transmitted to humans.
Faced with the issue of increasing resistance among foodborne pathogens and evidence that use of antimicrobials in food-producing animals contributes to the problem, FDA decided to change its policies on the evaluation and approval of new animal drugs. In the past, FDA evaluated the human health impact of the microbial effects of only certain uses of antimicrobial new animal drugs in animal feeds. Now it is necessary to consider the potential human health impact of the microbial effects associated with all uses of all classes of antimicrobial animal drugs intended for use in foodproducing animals. FDA is in the process of developing a new regulatory strategy outlining the types of data that are necessary to provide protection of the public health while enabling the use of safe and effective drugs for veterinary medicine. The strategy includes revision of the pre-approval safety assessment for new animal drug applications, use of risk assessment to determine the human health impact resulting from the use of antimicrobials in food animals, robust monitoring for changes in susceptibilities among foodborne pathogens to drugs that are important in both human and veterinary medicine, research, and risk management. The pre-approval risk assessment needs to consider both the importance of the drug to human medicine and the potential human exposure to resistant bacteria acquired from food-producing animals that are human pathogens or that can transfer their resistance to human pathogens. After the approval of antimicrobial drugs for use in food-producing animals, surveillance of resistance to antimicrobials belonging to classes considered important in human medicine is conducted. This will enhance the ability to detect the emergence of antimicrobial resistance in time to allow corrective strategies to be implemented. In addition, information on the amounts of antimicrobials given to food animals needs to be collected and compared with data from surveillance programs on antimicrobial resistance. The debate over the human health impact of antimicrobial drug use in food-producing animals has continued for more than 30 years. The identification and subsequent containment of resistance will help ensure the continued effectiveness of veterinary and human antimicrobial drugs for years to come. The ultimate outcome will be to prolong the efficacy of existing and new antimicrobial drugs that are desperately needed to control both human and animal disease and to minimize the spread of resistant zoonotic pathogens to humans through the food supply.
